HIV Therapy -- What Do We Know, and When Do We Know It?

Volume 349:2351-2352		December 11, 2003		Number 24

HIV Therapy — What Do We Know, and When Do We Know It?

Paul R. Skolnik, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

Purchase this article

Letters

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

Related Article
by Robbins, G. K.
Related Article
by Shafer, R. W.

PubMed Citation

It has often been stated that the central questions in therapyfor human immunodeficiency virus (HIV) infection are the samenow as they were when the epidemic started. When do we starttherapy, what do we start with, when should we switch, whatconstitutes failure of therapy, and why do our therapies fail?Information from clinical trials of various anti-HIV treatments,along with in vitro observations, has narrowed the choices.Often, the design and completion of these trials lag behindpractice, but they still serve several crucial purposes. Thestudies confirm what we think we know, disprove beliefs basedon . . . [Full Text of this Article]

Source Information

From the Center for HIV/AIDS Care and Research, Boston University Medical Center, Boston University School of Medicine, Boston.

Related Letters:

Comparison of Regimens as Initial Therapy for HIV
Clotet B., Skolnik P. R.
Extract | Full Text | PDF
N Engl J Med 2004; 350:1053-1054, Mar 4, 2004. Correspondence

This article has been cited by other articles:

Gebrekristos, H. T, Mlisana, K. P, Karim, Q. A. (2005). Patients' readiness to start highly active antiretroviral treatment for HIV. BMJ 331: 772-775 [Full Text]
Clotet, B., Skolnik, P. R. (2004). Comparison of Regimens as Initial Therapy for HIV. NEJM 350: 1053-1054 [Full Text]
(2004). ACTG 384 -- Complicated, but Worth the Work. AIDS Clin Care 2004: 1-1 [Full Text]

Comments and questions? Please contact us.